{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:20:12Z","timestamp":1787678412387,"version":"build-2784847793"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110210","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:40:40Z","timestamp":1783147240000},"page":"110210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lead-guided prodrug development of small molecules as GLP-1R agonists"],"prefix":"10.1016","volume":"180","author":[{"given":"Hannah","family":"Lentschat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habiba G.","family":"Aboelfotouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nabil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mennatallah","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Stichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abdel-Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf H.","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette G.","family":"Beck-Sickinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110210_bb0005","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Phelps","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110210_bb0010","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and National Prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110210_bb0015","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","author":"Kerr","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110210_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1538143","article-title":"Global burden and risk factors of type 2 diabetes mellitus from 1990 to 2021, with forecasts to 2050","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110210_bb0025","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1161\/CIRCRESAHA.115.306883","article-title":"Obesity and cardiovascular disease","volume":"118","author":"Ortega","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.bioorg.2026.110210_bb0030","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body Fatness and Cancer--Viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110210_bb0035","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(05)67483-1","article-title":"Obesity","volume":"366","author":"Haslam","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110210_bb0040","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00179.2022","article-title":"Obesity and chronic kidney disease","volume":"324","author":"Jiang","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2026.110210_bb0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bioorg.2026.110210_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jdi.12681","article-title":"Distribution and hormonal characterization of primary murine L cells throughout the gastrointestinal tract","volume":"9","author":"Suzuki","year":"2018","journal-title":"Journal of diabetes investigation"},{"key":"10.1016\/j.bioorg.2026.110210_bb0055","doi-asserted-by":"crossref","first-page":"E550","DOI":"10.1152\/ajpendo.00326.2004","article-title":"Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP","volume":"290","author":"Theodorakis","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2026.110210_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107833","article-title":"Labeling and characterization of human GLP-1-secreting L-cells in primary ileal organoid culture","volume":"31","author":"Goldspink","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2026.110210_bb0065","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2026.110210_bb0070","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1073\/pnas.89.18.8641","article-title":"Expression cloning of the pancreatic Beta cell receptor for the Gluco-incretin hormone glucagon-like peptide 1","volume":"89","author":"Thorens","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110210_bb0075","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like Peptide-1 (GLP-1) analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110210_bb0080","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1464-5491.2005.01567.x","article-title":"Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes","volume":"22","author":"Feinglos","year":"2005","journal-title":"Diabetic medicine: a journal of the British Diabetic Association"},{"key":"10.1016\/j.bioorg.2026.110210_bb0085","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bioorg.2026.110210_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Molecular metabolism"},{"key":"10.1016\/j.bioorg.2026.110210_bb0095","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","article-title":"A pharmacological and clinical overview of Oral Semaglutide for the treatment of type 2 diabetes","volume":"81","author":"Andersen","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110210_bb0100","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1073\/pnas.0605701104","article-title":"Small-molecule agonists for the glucagon-like peptide 1 receptor","volume":"104","author":"Knudsen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110210_bb0105","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2337\/db10-0689","article-title":"Novel small molecule glucagon-like Peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets","volume":"59","author":"Sloop","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2026.110210_bb0110","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110210_bb0115","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","volume":"406","author":"Horn","year":"2026","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bioorg.2026.110210_bb0120","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A small-molecule Oral agonist of the human glucagon-like Peptide-1 receptor","volume":"65","author":"Griffith","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110210_bb0125","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1111\/dom.16534","article-title":"Efficacy and safety of Danuglipron (PF-06882961) in adults with obesity: a randomized, placebo-controlled, dose-ranging phase 2b study","volume":"27","author":"Buckeridge","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bioorg.2026.110210_bb0135","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110210_bb0140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21445","article-title":"Development of safe drugs: the hERG challenge","volume":"38","author":"Kalyaanamoorthy","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110210_bb0145","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110210_bb0150","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1021\/acs.jmedchem.3c00320","article-title":"Discovery of novel 5,6-Dihydro-1,2,4-triazine derivatives as efficacious glucagon-like Peptide-1 receptor agonists","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110210_bb0155","doi-asserted-by":"crossref","first-page":"7662","DOI":"10.1021\/acs.jmedchem.5c00231","article-title":"Discovery of new Difluorocyclobutyl derivatives as effective glucagon-like Peptide-1 receptor agonists with reduced hERG inhibitory activities","volume":"68","author":"Miao","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110210_bb0160","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1021\/acsptsci.4c00503","article-title":"Comparison of protocols to test peptide stability in blood plasma and cell culture supernatants","volume":"7","author":"Kohler","year":"2024","journal-title":"ACS pharmacology & translational science"},{"key":"10.1016\/j.bioorg.2026.110210_bb0165","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.6b01915","article-title":"Development of selective Clk1 and \u22124 inhibitors for cellular depletion of Cancer-relevant proteins","volume":"60","author":"ElHady","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110210_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R binding and activation by peptide and non-peptide agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.110210_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.117128","article-title":"Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist Danuglipron using UHPLC-QToF-MS\/MS","volume":"267","author":"Jaiswal","year":"2026","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bioorg.2026.110210_bb0180","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/0002889738506861","article-title":"Stability of Esterases in stored blood fractions","volume":"34","author":"Braid","year":"1973","journal-title":"Am. Ind. Hyg. Assoc. J."},{"key":"10.1016\/j.bioorg.2026.110210_bb0185","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.bcp.2005.09.002","article-title":"Butyrylcholinesterase, Paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma","volume":"70","author":"Li","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110210_bb0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389200219666180821094502","article-title":"The impact of carboxylesterases in drug metabolism and pharmacokinetics","volume":"20","author":"Di","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bioorg.2026.110210_bb0195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0005-2760(83)90155-8","article-title":"Kinetic properties of human pancreatic carboxylesterase","volume":"754","author":"Wang","year":"1983","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2026.110210_bb0200","series-title":"Esterases, Lipases, and Phospholipases","year":"1994"},{"key":"10.1016\/j.bioorg.2026.110210_bb0205","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.abb.2009.12.005","article-title":"Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior","volume":"494","author":"Masson","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bioorg.2026.110210_bb0210","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1021\/acsmedchemlett.4c00371","article-title":"Enhanced plasma stability and potency of aryl\/acyloxy prodrugs of a BTN3A1 ligand","volume":"15","author":"Singh","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110210_bb0215","doi-asserted-by":"crossref","first-page":"15493","DOI":"10.1021\/acs.jmedchem.3c01681","article-title":"Discovery of tert-butyl Ester based 6-Diazo-5-oxo-l-norleucine prodrugs for enhanced metabolic stability and tumor delivery","volume":"66","author":"Novotn\u00e1","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110210_bb0220","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110210_bb0225","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4236\/pp.2024.158016","article-title":"Exploring Ester prodrugs: a comprehensive review of approaches, applications, and methods","volume":"15","author":"Zhou","year":"2024","journal-title":"PP"},{"key":"10.1016\/j.bioorg.2026.110210_bb0230","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm0303812","article-title":"Lessons learned from marketed and investigational prodrugs","volume":"47","author":"Ettmayer","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110210_bb0235","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:34:19Z","timestamp":1787675659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S0045206826007467"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110210","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lead-guided prodrug development of small molecules as GLP-1R agonists","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110210"}}